Prostate cancer progression after therapy of primary curative intent

A review of data from the prostate-specific antigen era


  • Mark Soloway M.D.,

    Corresponding author
    1. Department of Urology, University of Miami School of Medicine, Miami, Florida
    • Department of Urology, University of Miami School of Medicine, Dominion Towers, 1400 NW 10th Avenue, Miami, FL 33136
    Search for more papers by this author
    • Fax: (305) 243 4653

  • Mack Roach III M.D.

    1. Department of Radiation Oncology, Medical Oncology and Urology, University of California at San Francisco Comprehensive Cancer Center, San Francisco, California
    Search for more papers by this author



Radical prostatectomy and radiotherapy (RT), both radical therapies, are the standard treatments of curative intent for early prostate cancer. However, these therapies are not curative in all patients and, consequently, a substantial proportion of treated patients remain at risk of disease progression and/or cancer-related death.


This article presents contemporary data on the incidence of prostate-specific antigen (PSA) and clinical disease progression after primary therapy of curative intent in relation to commonly assessed pretreatment or pathologic disease characteristics.


The data highlight the substantial risk of progression for certain patient groups, such as those with Gleason score 8–10, cT3 disease, lymph node metastases, and/or pretreatment PSA levels > 20 ng/mL.


Improved and/or additional treatment options are needed for these patient groups. Cancer 2005. © 2005 American Cancer Society.